

Mast Therapeutics, Inc.  
Form SC 13G  
June 24, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Schedule 13G**

**Under the Securities Exchange Act of 1934**

(Amendment No. \_\_)\*

Mast Therapeutics, Inc.  
(Name of Issuer)

Common Stock  
(Title of Class of Securities)

576314108  
(CUSIP Number)

June 14, 2013  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

Edgar Filing: Mast Therapeutics, Inc. - Form SC 13G

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

CUSIP No. 576314108 **13G** Page 2 of 10 Pages

**NAMES OF  
REPORTING  
PERSONS**

Great Point Partners,  
LLC

**1.** I.R.S.  
IDENTIFICATION  
NO. OF ABOVE  
PERSON  
(ENTITIES ONLY):

37-1475292

**CHECK THE  
APPROPRIATE  
2. BOX IF A  
MEMBER OF A  
GROUP**

£  
(a)

£  
(b)

**3. SEC USE ONLY**

**CITIZENSHIP OR  
PLACE OF  
4. ORGANIZATION**

USA

**NUMBER OF SHARES    SOLE VOTING POWER**

**BENEFICIALLY**

**OWNED BY EACH    5.**  
0

**REPORTING PERSON**

**SHARED VOTING POWER**

**WITH**

**6.**  
8,700,000<sup>1</sup>

**SOLE DISPOSITIVE POWER**

**7.**  
0

**8.SHARED DISPOSITIVE POWER**

8,700,000<sup>1</sup>

**AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON**

**9.**  
8,700,000<sup>1</sup>

**CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES** £

**10.** (See Instructions)

**PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)**

**11.**  
8.77%<sup>1, 2</sup>

**TYPE OF REPORTING PERSON (See Instructions)**

**12.**

IA

<sup>1</sup>Includes 2,900,000 shares of Common Stock issuable upon exercise of warrants owned by Biomedical Value Fund, LP, Biomedical Offshore Value Fund, Ltd., Biomedical Institutional Value Fund, LP, Class D Series of GEF-PS, LP,

Edgar Filing: Mast Therapeutics, Inc. - Form SC 13G

David J. Morrison, and WS Investments III, LLC.

<sup>2</sup>Based on a total of 96,265,286 shares of Common Stock outstanding, as reported by the Issuer on a prospectus supplement filed with the SEC on June 17, 2013.

CUSIP No. 576314108 **13G** Page 3 of 10 Pages

**NAMES OF  
REPORTING  
PERSONS**

Dr. Jeffrey R. Jay,  
M.D.

**1.**

I.R.S.  
IDENTIFICATION  
NO. OF ABOVE  
PERSON  
(ENTITIES ONLY):

**CHECK THE  
APPROPRIATE**

**2. BOX IF A  
MEMBER OF A  
GROUP**

£  
(a)

£  
(b)

**3. SEC USE ONLY**

**CITIZENSHIP OR  
PLACE OF  
ORGANIZATION**

**4.**

USA

**SOLE VOTING POWER**

**5.**  
0<sup>1</sup>

**NUMBER OF SHARES**

**6. SHARED VOTING POWER**

**BENEFICIALLY**

**OWNED BY EACH**

**REPORTING PERSON**

**WITH**

8,700,000<sup>1</sup>

**SOLE DISPOSITIVE POWER**

7.  
0<sup>1</sup>

**SHARED DISPOSITIVE POWER**

8.  
8,700,000<sup>1</sup>

**AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON**

9.  
8,700,000<sup>1</sup>

**CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES** £  
(See Instructions)

10.

**PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)**

11.  
8.77%<sup>1, 2</sup>

**TYPE OF REPORTING PERSON** (See Instructions)

12.

IN

CUSIP No. 576314108 **13G** Page 4 of 10 Pages

**NAMES OF  
REPORTING  
PERSONS**

Mr. David Kroin

**1.**

I.R.S.  
IDENTIFICATION  
NO. OF ABOVE  
PERSON  
(ENTITIES ONLY):

**CHECK THE  
APPROPRIATE**

**2. BOX IF A  
MEMBER OF A  
GROUP**

£  
(a)

£  
(b)

**3. SEC USE ONLY**

**CITIZENSHIP OR  
PLACE OF  
ORGANIZATION**

**4.**

USA

**SOLE VOTING POWER**

**5.**  
0

**NUMBER OF SHARES  
BENEFICIALLY**

**6. SHARED VOTING POWER**

**OWNED BY EACH  
REPORTING PERSON**

8,700,000<sup>1</sup>

**WITH**



**SOLE DISPOSITIVE POWER**

7.  
0

**SHARED DISPOSITIVE POWER**

8.  
8,700,000<sup>1</sup>

**AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON**

9.  
8,700,000<sup>1</sup>

**CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES** £

10. (See Instructions)

**PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)**

11.  
8.77%<sup>1,2</sup>

**TYPE OF REPORTING PERSON** (See Instructions)

12.

IN

**Item 1.**

(a) Name of Issuer

Mast Therapeutics, Inc.

(b) Address of Issuer's Principal Executive Offices

12390 El Camino Real, Suite 150, San Diego, CA 92130

**Item 2.**

(a) Name of Person Filing

Great Point Partners, LLC  
Dr. Jeffrey R. Jay, M.D.  
Mr. David Kroin

The Reporting Persons have entered into a Joint Filing Agreement, dated June 24, 2013, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

(b) Address of Principal Business Office, or if none, Residence

The address of the principal business office of each of the Reporting Persons is

165 Mason Street, 3rd Floor  
Greenwich, CT 06830

(c) Citizenship

Great Point Partners, LLC is a limited liability company organized under the laws of the

State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States.

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

576314108

**Item 3.** If this statement is filed pursuant to §240.13d-1(b) or 240.13d.2(b) or (c), check whether the person filing is a:

Not Applicable.

(a)  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)

(b)  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)  Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c).

(d)  Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

CUSIP No. 576314108 **13G** Page 6 of 10 Pages

- (f) £ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
- (g) £ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
- (h) £ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) £ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) £ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

#### **Item 4. Ownership**

Biomedical Value Fund, L.P. (“BVF”) is the record owner of 2,227,496 shares of Common Stock (the “BVF Shares”). Great Point Partners, LLC (“Great Point”) is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as senior managing member of Great Point, and Mr. David Kroin (“Mr. Kroin”), as special managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares. In addition, BVF is the record owner of warrants to purchase 1,113,748 shares of Common Stock.

Biomedical Offshore Value Fund, Ltd. (“BOVF”) is the record owner of 1,370,949 shares of Common Stock (the “BOVF Shares”). Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares. In addition, BOVF is the record owner of warrants to purchase 685,475 shares of Common Stock.

Biomedical Institutional Value Fund, L.P. (“BIVF”) is the record owner 806,442 shares of Common Stock (the “BIVF Shares”). Great Point is the investment manager of BIVF, and by virtue of such status may be deemed to be the beneficial owner of the BIVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BIVF Shares, and therefore may be deemed to be the beneficial owner of the BIVF Shares. In addition, BIVF is the record owner of warrants to purchase 403,221 shares of Common Stock.

Class D Series of GEF-PS, LP (“GEF-PS”) is the record owner of 1,143,536 shares of Common Stock (the “GEF-PS Shares”). Great Point is the investment manager of GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the GEF-PS Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the GEF-PS Shares, and therefore may be deemed to be the beneficial owner of the GEF-PS Shares. In addition, GEF-PS is the record owner of warrants to purchase 571,768 shares of Common Stock.

WS Investments III, LLC (“WS”) is the record owner of 205,836 shares of Common Stock (the “WS Shares”). Great Point is the investment manager with respect to the WS Shares, and by virtue of such status may be deemed to be the beneficial owner of the WS Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the WS Shares, and therefore may be deemed to be the beneficial owner of the WS Shares. In addition, WS is is the

record owner of warrants to purchase 102,918 of Common Stock.

CUSIP No. 576314108 **13G** Page 7 of 10 Pages

David J. Morrison (“Morrison”) is the record owner of 45,741 shares of Common Stock (the “Morrison Shares”). Great Point is the investment manager with respect to the Morrison Shares, and by virtue of such status may be deemed to be the beneficial owner of the Morrison Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the Morrison Shares, and therefore may be deemed to be the beneficial owner of the Morrison Shares. In addition, Morrison is the record owner of warrants to purchase 22,871 shares of Common Stock.

Notwithstanding the above, Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of the BVF Shares, the BOVF Shares, the BIVF Shares, the GEF-PS Shares, the Morrison Shares, the WS Shares, and the shares of Common Stock underlying warrants described above, except to the extent of their respective pecuniary interests.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

**1. Great Point Partners, LLC**

(a) Amount beneficially owned: 8,700,000<sup>3</sup>

(b) Percent of class: 8.77%<sup>3,4</sup>

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: - 0 -

(ii) Shared power to vote or to direct the vote: 8,700,000<sup>3</sup>

(iii) Sole power to dispose or to direct the disposition of: - 0 -

(iv) Shared power to dispose or to direct the disposition of: 8,700,000<sup>3</sup>

**2. Dr. Jeffrey R. Jay, M.D.**

(a) Amount beneficially owned: 8,700,000<sup>3</sup>

(b) Percent of class: 8.77%<sup>3,4</sup>

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 0.

(ii) Shared power to vote or to direct the vote: 8,700,000<sup>3</sup>

(iii) Sole power to dispose or to direct the disposition of: 0.

(iv) Shared power to dispose or to direct the disposition of: 8,700,000<sup>3</sup>

Edgar Filing: Mast Therapeutics, Inc. - Form SC 13G

Includes 2,900,000 shares of Common Stock issuable upon exercise of warrants owned by Biomedical Value Fund,<sup>3</sup> LP, Biomedical Offshore Value Fund, Ltd., Biomedical Institutional Value Fund, LP, Class D Series of GEF-PS, LP, David J. Morrison, and WS Investments III, LLC.

<sup>4</sup>Based on a total of 96,265,286 shares of Common Stock outstanding, as reported by the Issuer on a prospectus supplement filed with the SEC on June 17, 2013.

CUSIP No. 576314108 **13G** Page 8 of 10 Pages

**3. Mr. David Kroin**

(a) Amount beneficially owned: 8,700,000<sup>3</sup>

(b) Percent of class: 8.77%<sup>3,4</sup>

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 0.

(ii) Shared power to vote or to direct the vote: 8,700,000<sup>3</sup>

(iii) Sole power to dispose or to direct the disposition of: 0.

(iv) Shared power to dispose or to direct the disposition of: 8,700,000<sup>3</sup>

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

**Item 6. Ownership of More than Five Percent on Behalf of Another Person:**

See Item 4.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company**

Not Applicable.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable.

**Item 9. Notice of Dissolution of Group**

Not Applicable.

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that



purpose or effect.

CUSIP No. 576314108 **13G**Page 9 of 10 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 24, 2013

GREAT POINT PARTNERS,  
LLC

By: /s/ Dr. Jeffrey R. Jay, M.D.  
Dr. Jeffrey R. Jay, M.D.,  
as senior managing member

/s/ Dr. Jeffrey R. Jay, M.D.  
DR. JEFFREY R. JAY, M.D.

/s/ Mr. David Kroin  
MR. DAVID KROIN

Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G

The undersigned hereby agree as follows:

- (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and
  
- (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: June 24, 2013

GREAT POINT PARTNERS,  
LLC

By: /s/ Dr. Jeffrey R. Jay, M.D.  
Dr. Jeffrey R. Jay, M.D.,  
as senior managing member

/s/ Dr. Jeffrey R. Jay, M.D.  
DR. JEFFREY R. JAY, M.D.

/s/ Mr. David Kroin  
MR. DAVID KROIN